Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2023-09-25 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Regulatory Filings Classification · 1% confidence The document is a formal 'Company Announcement' (No. 41) issued by Genmab A/S regarding the European Commission's approval of a new drug, TEPKINLY. It details the regulatory milestone, clinical trial results, and safety information. As it is a general regulatory announcement regarding company operations and product approvals that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a Regulatory Filing (RNS).
2023-09-25 English
6-K
Foreign Filer Report
2023-09-13 English
6-K
Foreign Filer Report
2023-09-12 English
Share Issue/Capital Change 2023
Share Issue/Capital Change Classification · 1% confidence The document is a 'Company Announcement' from Genmab A/S detailing a 'Capital Increase... as a Result of Employee Warrant Exercise'. It specifies the number of shares issued, the subscription prices, and the resulting total share capital. This content directly relates to changes in the company's capital structure due to financing/issuance activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it mentions an attachment, the primary content is the announcement itself detailing the capital change, not just announcing the publication of a report, making CAP a better fit than RPA or RNS.
2023-09-12 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 1% confidence The document is a formal company announcement from Genmab regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory compliance with the Danish Capital Markets Act. This falls squarely under the definition of a 'Share Issue/Capital Change' (SHA) announcement.
2023-09-12 English
6-K
Foreign Filer Report
2023-09-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.